Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Shaefer

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
The Annals of Pharmacotherapy|January 11, 1992
Treatment of valproic acid-associated hepatic failure with orthotopic liver transplantationE A Bell, M S Shaefer, R S Markin, et al.
The Journal of Infectious Diseases|February 15, 2001
Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET StudyK Henry, R J Wallace, P C Bellman, et al.
Transplantation Proceedings|June 1, 1991
Fungal infections in liver allograft recipientsP Castaldo, R J Stratta, R P Wood, et al.
AIDS (London, England)|May 12, 2000
Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infectionJ J Eron, E S Yetzer, P J Ruane, et al.
Archives of Surgery (Chicago, Ill. : 1960)|January 11, 1992
A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapyR J Stratta, M S Shaefer, K A Cushing, et al.
Transplantation|August 1, 1993
Falsely elevated FK-506 levels caused by sampling through central venous cathetersM S Shaefer, D S Collier, M C Haven, et al.
Clinical Pharmacology and Therapeutics|March 1, 1995
Pharmacokinetics of tacrolimus in liver transplant patientsW J Jusko, W Piekoszewski, G B Klintmalm, et al.
Transplantation Proceedings|April 1, 1990
Donor selection for orthotopic liver transplantation: lack of an effect of gender or cytomegalovirus (CMV) statusR J Stratta, R P Wood, A N Langnas, et al.
Transplantation Proceedings|February 1, 1991
Ganciclovir therapy for cytomegalovirus disease in liver transplant recipientsM S Shaefer, R J Stratta, R S Markin, et al.
HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The Annals of Pharmacotherapy|January 11, 1992
Treatment of valproic acid-associated hepatic failure with orthotopic liver transplantationE A Bell, M S Shaefer, R S Markin, et al.
The Journal of Infectious Diseases|February 15, 2001
Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET StudyK Henry, R J Wallace, P C Bellman, et al.
Transplantation Proceedings|June 1, 1991
Fungal infections in liver allograft recipientsP Castaldo, R J Stratta, R P Wood, et al.
AIDS (London, England)|May 12, 2000
Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infectionJ J Eron, E S Yetzer, P J Ruane, et al.
Archives of Surgery (Chicago, Ill. : 1960)|January 11, 1992
A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapyR J Stratta, M S Shaefer, K A Cushing, et al.
Transplantation|August 1, 1993
Falsely elevated FK-506 levels caused by sampling through central venous cathetersM S Shaefer, D S Collier, M C Haven, et al.
Clinical Pharmacology and Therapeutics|March 1, 1995
Pharmacokinetics of tacrolimus in liver transplant patientsW J Jusko, W Piekoszewski, G B Klintmalm, et al.
Transplantation Proceedings|April 1, 1990
Donor selection for orthotopic liver transplantation: lack of an effect of gender or cytomegalovirus (CMV) statusR J Stratta, R P Wood, A N Langnas, et al.
Transplantation Proceedings|February 1, 1991
Ganciclovir therapy for cytomegalovirus disease in liver transplant recipientsM S Shaefer, R J Stratta, R S Markin, et al.
HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.
Pageof 3